Xhance Alternatives Compared
Xhance (fluticasone) | Nucala (mepolizumab) | Dupixent (dupilumab) |
|
---|
Xhance (fluticasone) | Nucala (mepolizumab) | Dupixent (dupilumab) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription and OTC
Prescribed for Rhinitis, Chronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis Without Nasal Polyps. Xhance may also be used for purposes not listed in this medication guide. |
Prescription only
Nucala is a biologic that works by blocking the action of IL-5 which is the main cytokine responsible for the survival and production of eosinophils. Nucala may be used to treat severe eosinophilic... View more |
Prescription only
Dupixent injection is usually given every 1 to 4 weeks to treat asthma, eczema, chronic rhinosinusitis, COPD, eosinophilic esophagitis, or prurigo nodularis. Injection site reactions and eye problems... View more |
Related suggestions Chronic Rhinosinusitis With Nasal Polyps
|
|||||||||||||||||||||||
More about Xhance (fluticasone) | More about Nucala (mepolizumab) | More about Dupixent (dupilumab) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Xhance has an average rating of 6.4 out of 10 from a total of 23 ratings on Drugs.com. 52% of reviewers reported a positive effect, while 35% reported a negative effect. |
Nucala has an average rating of 7.3 out of 10 from a total of 99 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 16% reported a negative effect. |
Dupixent has an average rating of 7.2 out of 10 from a total of 500 ratings on Drugs.com. 62% of reviewers reported a positive effect, while 20% reported a negative effect. |
||||||||||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Xhance side effects |
View all Nucala side effects |
View all Dupixent side effects |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Xhance prices |
View all Nucala prices |
View all Dupixent prices |
||||||||||||||||||||||||
Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Other fluticasone brands include: Flonase, Flonase Allergy Relief, Flonase Sensimist, Ticanase |
N/A |
N/A |
||||||||||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
8 hours |
528 hours |
N/A |
||||||||||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category N
Not classified
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 51 drugs are known to interact with Xhance:
|
A total of 21 drugs are known to interact with Nucala:
|
A total of 92 drugs are known to interact with Dupixent:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
N/A |
November 04, 2015 |
March 28, 2017 |
||||||||||||||||||||||||
WADA Class View classifications | ||||||||||||||||||||||||||
N/A |
N/A |
|||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient Resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.